11-dehydro-txb2

Introduction

To understand associated biological information of 11-dehydro-txb2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 11-dehydro-txb2?

11-dehydro-txb2 is suspected in Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis, Chronic ischemic heart disease NOS, Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-Dependent and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 11-dehydro-txb2

MeSH term MeSH ID Detail
Diabetes Mellitus D003920 90 associated lipids
Inflammation D007249 119 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Asthma D001249 52 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Thrombosis D013927 49 associated lipids
Cerebral Hemorrhage D002543 13 associated lipids
Brain Ischemia D002545 89 associated lipids
Per page 10 20 | Total 20

PubChem Associated disorders and diseases

What pathways are associated with 11-dehydro-txb2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

What functions are associated with 11-dehydro-txb2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

What genes are associated with 11-dehydro-txb2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 11-dehydro-txb2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with 11-dehydro-txb2

Download all related citations
Per page 10 20 50 100 | Total 283
Authors Title Published Journal PubMed Link
Minuz P et al. Determinants of platelet activation in human essential hypertension. 2004 Hypertension pmid:14656953
Alusik S et al. The inhibitory effect of statins on urinary 11-dehydrothromboxane levels. 2010 Int Angiol pmid:20502413
Sadilkova L et al. The effect of selected pre-analytical phase variables on plasma thromboxane Aâ‚‚ measurements in humans. 2013 Int J Lab Hematol pmid:22908995
Oosaki R et al. Urinary excretion of leukotriene E4 and 11-dehydrothromboxane B2 in patients with spontaneous asthma attacks. 1997 Int. Arch. Allergy Immunol. pmid:9414142
De Candia E et al. Abnormal pH-sensing of platelet Na+/H+ exchanger in patients with cardiac syndrome X. 2005 Int. J. Cardiol. pmid:15837078
Uyama O et al. Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction. 1992 Intern. Med. pmid:1392173
Shen L et al. In vivo oxidation, platelet activation and simultaneous occurrence of natural immunity in atherosclerosis-prone mice. 2011 Isr. Med. Assoc. J. pmid:21845968
Vazzana N et al. Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype. 2013 J Am Heart Assoc pmid:23557750
Kakouros N et al. Risk Factors for Nonplatelet Thromboxane Generation After Coronary Artery Bypass Graft Surgery. 2016 J Am Heart Assoc pmid:27068626
Lattanzio S et al. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. 2014 J Am Heart Assoc pmid:25037197
Santilli F et al. Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. 2014 J Am Heart Assoc pmid:25037196
Schwartz JI et al. Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. 2007 J Clin Pharmacol pmid:17925592
Roethig HJ et al. A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. 2008 J Clin Pharmacol pmid:18319361
Lauring B et al. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. 2009 J Clin Pharmacol pmid:19833861
Pape HC et al. Does the reamer type influence the degree of lung dysfunction after femoral nailing following severe trauma? An animal study. 1994 J Orthop Trauma pmid:7965291
Thomson VS et al. Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events. 2009 Oct-Dec J Postgrad Med pmid:20083870
Lindström T et al. The effect of unreamed and reamed intramedullary nailing on the urinary excretion of prostacyclin and thromboxane A2 metabolites in patients with tibial shaft fractures. 1998 J Trauma pmid:9783614
Stanke-Labesque F et al. Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. 2009 J. Allergy Clin. Immunol. pmid:19596146
Ciabattoni G et al. Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. 1993 J. Am. Coll. Cardiol. pmid:8473644
Benowitz NL et al. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. 1993 J. Am. Coll. Cardiol. pmid:7691912
Santilli F et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. 2006 J. Am. Coll. Cardiol. pmid:16412866
Cuiper LL et al. Systemic and pulmonary hypertension after abrupt cessation of prostacyclin: role of thromboxane A2. 1996 J. Appl. Physiol. pmid:8847301
Gremmel T et al. Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy. 2013 J. Atheroscler. Thromb. pmid:23739624
Yi X et al. Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50T and COX-2 G765C. 2013 J. Atheroscler. Thromb. pmid:22972377
Böhm E et al. 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. 2004 J. Biol. Chem. pmid:14668348
Vazzana N et al. Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress. 2012 J. Clin. Endocrinol. Metab. pmid:22761461
Cesari M et al. Oxidative damage, platelet activation, and inflammation to predict mobility disability and mortality in older persons: results from the health aging and body composition study. 2012 J. Gerontol. A Biol. Sci. Med. Sci. pmid:22389462
Laffi G et al. Defective aggregation in cirrhosis is independent of in vivo platelet activation. 1996 J. Hepatol. pmid:8738730
Foegh ML et al. Urinary thromboxane A2 metabolites in patients presenting in the emergency room with acute chest pain. 1994 J. Intern. Med. pmid:8308478
Morrow JD et al. Increased formation of thromboxane in vivo in humans with mastocytosis. 1999 J. Invest. Dermatol. pmid:10417625
Romano M et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. 2000 J. Investig. Med. pmid:10822898
Bosetti F et al. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. 2003 J. Neurochem. pmid:12694395
Cullen L et al. Selective cyclooxygenase-2 inhibition by nimesulide in man. 1998 J. Pharmacol. Exp. Ther. pmid:9808683
Catella-Lawson F et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. 1999 J. Pharmacol. Exp. Ther. pmid:10215647
Maga P et al. 11-dehydro thromboxane B2 levels after percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease during a one year follow-up period. 2016 J. Physiol. Pharmacol. pmid:27511998
Olson MT et al. Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. 2012 J. Thromb. Haemost. pmid:23072449
Ferroni P et al. Platelet activation in type 2 diabetes mellitus. 2004 J. Thromb. Haemost. pmid:15304032
Ohmori T et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. 2006 J. Thromb. Haemost. pmid:16706971
De Cristofaro R et al. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. 2003 J. Thromb. Haemost. pmid:12871497
Li C et al. Reversal of the anti-platelet effects of aspirin and clopidogrel. 2012 J. Thromb. Haemost. pmid:22268852
Lemkes BA et al. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. 2012 J. Thromb. Haemost. pmid:22252020
Santilli F et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. 2010 J. Thromb. Haemost. pmid:20088941
Hartanto MD et al. Urinary 11-dehydro-thromboxane B₂ and 2,3-dinor-6-keto-prostaglandin-F₁α in healthy post-menopausal and pre-menopausal women receiving aspirin 100 mg. 2012 J. Thromb. Thrombolysis pmid:22311294
Addad F et al. Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. 2010 J. Thromb. Thrombolysis pmid:19381450
Lin JS et al. The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in arteriogenic impotence. 1992 J. Urol. pmid:1635125
Thomason J et al. Platelet cyclooxygenase expression in normal dogs. 2011 Sep-Oct J. Vet. Intern. Med. pmid:21985141
Dudley A et al. Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin. 2013 Jan-Feb J. Vet. Intern. Med. pmid:23278865
Fritsma GA et al. Monitoring the antiplatelet action of aspirin. 2001 JAAPA pmid:11523339
Davì G et al. Platelet activation in obese women: role of inflammation and oxidant stress. 2002 Oct 23-30 JAMA pmid:12387653
Mills JL et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. 1999 JAMA pmid:10432033